Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Salud, A.
Escudero, P.
Feliu, J.
Lopez-Gomez, L.
Bolanos, M.
Galan, A.
Yubero, A.
Vicent, J. M.
Losa, F.
Gonzalez-Baron, M.
机构：
[1] Hosp Arnau Vilanova, Med Oncol Serv, Lleida, Spain
[2] Hosp Lozano Blesa, Med Oncol Serv, Zaragoza, Spain
[3] Hosp La Paz, Med Oncol Serv, Madrid, Spain
[4] Hosp Virgen Salud, Med Oncol Serv, Toledo, Spain
[5] Hosp San Pedro Alcantara, Med Oncol Serv, Caceres, Spain
[6] Hosp Sagunto, Med Oncol Serv, Valencia, Spain
[7] Hosp Obispo Polanco, Med Oncol Serv, Teruel, Spain
[8] Hosp Gen Univ, Med Oncol Serv, Valencia, Spain
[9] Hosp Creu Roja De Barcelona, Med Oncol Serv, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [41] Capecitabine combined with oxaliplatin (XELOX) as first-line chemotherapy in colorectal cancer with liver metastases
    Mahfouf, H.
    Djeddi, H.
    Belhadef, S.
    Bouzid, K.
    Bentabak, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis
    Zhao, G.
    Gao, P.
    Yang, K. H.
    Tian, J. H.
    Ma, B.
    COLORECTAL DISEASE, 2010, 12 (07) : 615 - 623
  • [43] XELOX (capecitabine plus oxaliplatin), a safe and active first-line regimen for elderly patients with metastatic colorectal cancer (MCRC):: Post-hoc analysis of a large phase II study.
    Twelves, C
    Butts, C
    Cassidy, J
    Conroy, T
    De Braud, F
    Díaz-Rubio, E
    Tabernero, J
    Schöffski, P
    Figer, A
    Van Cutsem, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 258S - 258S
  • [44] Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    Zeuli, M
    Nardoni, C
    Pino, MS
    Gamucci, T
    Gabriele, A
    Ferraresi, V
    Giannarelli, D
    Cognetti, F
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1378 - 1382
  • [45] Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): A pooled analysis of randomized phase II-III trials
    Porschen, R.
    Arkenau, H.
    Arnold, D.
    Cassidy, J.
    Diaz-Rubio, E.
    Douillard, J.
    Grothey, A.
    Hinke, A.
    Schmiegel, W.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    E van Meerten
    F A L M Eskens
    E C van Gameren
    L Doorn
    A van der Gaast
    British Journal of Cancer, 2007, 96 : 1348 - 1352
  • [47] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
    Fonseca, P. J.
    Solis, P.
    Vieitez, J. M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Frunza, M.
    Uriol, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
  • [48] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    van Meerten, E.
    Eskens, F. A. L. M.
    van Gameren, E. C.
    Doorn, L.
    van der Gaast, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (09) : 1348 - 1352
  • [49] Capecitabine single agent or in combination in the routine first-line treatment of a predominantly elderly population with metastatic colorectal cancer (MCRC)
    Schroeder, J.
    Goehler, T.
    Grothe, W.
    Tschechne, B.
    Valdix, A. R.
    Harich, H. D.
    Kluensch, F.
    Hofheinz, R. D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 337 - 337
  • [50] XELOX AND BEVACIZUMAB AS FIRST-LINE TREATMENT IN FIT ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER: THE BOXE STUDY
    Rosati, Gerardo
    Avallone, Antonio
    Aprile, Giuseppe
    Butera, Alfredo
    De Pauli, Federica
    Reggiardo, Giorgio
    Bilancia, Domenico
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
12345